Health is a unity and harmony within the mind, body and spirit which is unique to each person, and is as defined by that person. The level of wellness or health is, in part, determined by the ability to deal with and defend against stress. Health is determined by physiological, psychological, socio-cultural, spiritual, and developmental stage variables.

Call for greater use of comparative effectiveness studies to help advance disease management

Osteoporosis :: Call for greater use of comparative effectiveness studies to help advance disease management

The largest retrospective, observational study comparing two osteoporosis therapies on the basis of fracture reduction was presented today at the Seventh European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO) in Porto, Portugal.

Patients taking the osteoporosis treatment risedronate (Actonel?, risedronate sodium) were almost half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment, according to the REAL (RisedronatE, ALendronate) study.

Only a few "head-to-head" observational studies, or comparative effectiveness studies, have been conducted in the field of osteoporosis. Beyond the safety and efficacy data provided by placebo-controlled randomized trials, healthcare professionals have increasingly expressed interest in more head-to-head data comparing therapies on the relevant clinical endpoint, fracture.

Comparative effectiveness filling the knowledge gap

Today experts are highlighting that well-designed comparative effectiveness studies can help advance our clinical knowledge where little data exists. Dr. Olaf Klungel, Associate Professor, Division of Pharmacoepidemiology and Pharmacotherapy, University of Utrecht, Netherlands, is a leading expert in the field of comparative effectiveness study design.

"There is a wealth of data available from large healthcare databases that enable us to research important clinical questions," said Dr. Klungel, "Robust methodology exists for comparing different therapies through observational database analysis. We must advance physicians' understanding and evaluation of these studies so that they can confidently integrate the information into their clinical decisions, when appropriate."

Physicians want to know the impact of their clinical decisions on the disease outcomes that matter most to patients. In the cardiovascular area, observational methods have been applied to compare antihypertensive therapies on the relevant outcomes of heart attack and stroke.2,3 In osteoporosis, similar methods are now being applied to compare therapies on the basis of fracture.

REAL life results in osteoporosis

REAL, a retrospective cohort study, included 33,830 women newly treated with once-weekly doses of either Actonel or alendronate in 'real-life' clinical practice. Results showed that at 12 months patients on Actonel had a 43% (p=0.01) lower incidence of hip fractures compared to patients on alendronate. At 6 months similar results were seen, with Actonel resulting in a 46% (p=0.02) greater reduction in risk of hip fracture versus alendronate. The two treatments were not compared on the basis of side effects in this study.

"In osteoporosis, it is unlikely that prospective, head-to-head clinical fracture trials will be conducted due to the large number of patients required to show a difference between two effective therapies," said Professor Delmas, REAL study author, Universit? Claude Bernard, Lyon. "Large, comparative, retrospective analyses, like the REAL study, are one way to fill the knowledge gap and should be considered in the total body of evidence for a drug to optimise treatment decisions and enhance patient care."

Recently posted related articles on Osteoporosis :

1. Osteoporosis :: IOF recognizes ESCEO European guidance for osteoporosis diagnosis and management
2. Osteoporosis :: New research on structure of bones raises questions for treatment of osteoporosis
3. Osteoporosis :: Tea prevents osteoporosis, improves bone density in women
4. Osteoporosis :: UWM researcher finds that food labels confuse consumers
5. Osteoporosis :: Aclasta Reclast prevents additional fractures in hip fracture patients with osteoporosis
6. Osteoporosis :: Scientists learn role of oxidative stress in estrogen-related bone loss
7. Osteoporosis :: International study strengthens case for daily calcium pill
8. Osteoporosis :: Calcium supplements reduce bone loss, prevent osteoporosis
9. Osteoporosis :: FDA approves Reclast injection for women with postmenopausal osteoporosis
10. Osteoporosis :: Reclast receives US regulatory approval as first and only once-yearly treatment for women with postmenopausal osteoporosis